Actinogen Extends ASX Trading Halt as It Weighs Major Capital Raising

The latest announcement is out from Actinogen Medical ( (AU:ACW) ).

Actinogen Medical has requested a continuation of its trading halt on the ASX as it considers a proposed material capital raising, following a positive recommendation from its Data Monitoring processes. The halt, approved by the exchange, will remain in place until the company releases further details on the funding or trading resumes on 2 February 2026, signalling a potentially significant financing event to support its late-stage clinical programs and broader development of Xanamem in Alzheimer’s and related neurological conditions.

The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical is an ASX-listed biotechnology company developing Xanamem, a first-in-class oral therapy targeting dysregulated brain cortisol for neurological and neuropsychiatric diseases. Its lead focus is on Alzheimer’s disease, with additional work in treatment-resistant depression and potential future indications such as Fragile X Syndrome, aiming to address substantial unmet need in cognitive and mood disorders through novel cortisol-control mechanisms.

Average Trading Volume: 5,718,981

Technical Sentiment Signal: Hold

Current Market Cap: A$153.2M

For detailed information about ACW stock, go to TipRanks’ Stock Analysis page.